- Home
- KROS vs EU Comparison
KROS vs EU Comparison
Compare KROS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- EU
- Stock Information
- Founded
- KROS 2015
- EU 2009
- Country
- KROS United States
- EU United States
- Employees
- KROS N/A
- EU N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- KROS Health Care
- EU Basic Materials
- Exchange
- KROS Nasdaq
- EU Nasdaq
- Market Cap
- KROS 589.8M
- EU 669.1M
- IPO Year
- KROS 2020
- EU N/A
- Fundamental
- Price
- KROS $11.84
- EU $3.56
- Analyst Decision
- KROS Buy
- EU Strong Buy
- Analyst Count
- KROS 11
- EU 2
- Target Price
- KROS $45.33
- EU $6.50
- AVG Volume (30 Days)
- KROS 2.1M
- EU 1.4M
- Earning Date
- KROS 02-26-2025
- EU 11-14-2024
- Dividend Yield
- KROS N/A
- EU N/A
- EPS Growth
- KROS N/A
- EU N/A
- EPS
- KROS N/A
- EU N/A
- Revenue
- KROS $651,000.00
- EU $44,972,063.00
- Revenue This Year
- KROS $303.27
- EU N/A
- Revenue Next Year
- KROS N/A
- EU $55.73
- P/E Ratio
- KROS N/A
- EU N/A
- Revenue Growth
- KROS 8037.50
- EU N/A
- 52 Week Low
- KROS $9.78
- EU $3.02
- 52 Week High
- KROS $73.00
- EU $5.05
- Technical
- Relative Strength Index (RSI)
- KROS 24.87
- EU 53.61
- Support Level
- KROS $10.95
- EU $3.26
- Resistance Level
- KROS $11.63
- EU $3.46
- Average True Range (ATR)
- KROS 0.87
- EU 0.19
- MACD
- KROS 1.31
- EU 0.03
- Stochastic Oscillator
- KROS 30.60
- EU 54.24
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's material properties and projects are the Rosita Project located in Texas, the Alta Mesa Uranium project in Texas, the Crownpoint and Hosta Butte Uranium Project located in New Mexico, the Dewey Burdock Project located in South Dakota, and the Gas Hills Project located in Wyoming.